Trials / Completed
CompletedNCT00930163
A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 218 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled study to evaluate the effects of lebrikizumab in patients with asthma who remain inadequately controlled while on chronic therapy with inhaled corticosteroids (ICS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lebrikizumab (MILR1444A) | Subcutaneous repeating dose |
| DRUG | placebo | Subcutaneous repeating dose |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-07-01
- Completion
- 2010-09-01
- First posted
- 2009-06-30
- Last updated
- 2016-11-29
Source: ClinicalTrials.gov record NCT00930163. Inclusion in this directory is not an endorsement.